DNER and plasma cell myeloma: However, in clinical trials investigating the BET inhibitor OTX015 in multiple myeloma, AML, and diffuse large B-cell lymphoma, MYC amplification was found incapable of predicting the drug response to the BET inhibitor [165,166].